双鹭药业
(002038)
| 流通市值：48.15亿 | | | 总市值：58.05亿 |
| 流通股本：8.52亿 | | | 总股本：10.27亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 762,592,919.17 | 644,080,637.12 | 519,399,513.15 | 383,945,973.08 |
| 交易性金融资产 | 473,016,131.79 | 512,011,845.82 | 498,947,645.02 | 569,625,262.62 |
| 应收票据及应收账款 | 76,020,680.05 | 83,131,468.65 | 80,548,555.11 | 90,392,068.08 |
| 应收账款 | 76,020,680.05 | 83,131,468.65 | 80,548,555.11 | 90,392,068.08 |
| 应收款项融资 | 39,200 | 12,439.8 | 381,807.8 | 263,340 |
| 预付款项 | 103,016,326.12 | 133,637,601.12 | 164,728,343.58 | 117,179,710.95 |
| 其他应收款合计 | 8,846,760.77 | 12,087,355.31 | 14,070,714.58 | 14,907,460.95 |
| 存货 | 141,553,294.83 | 555,144,308.32 | 681,813,145.03 | 394,807,069.61 |
| 一年内到期的非流动资产 | - | - | 21,792,000 | 231,950,750.02 |
| 其他流动资产 | 5,987,722.84 | 108,772,188.14 | 112,280,530.88 | 783,328,708.08 |
| 流动资产合计 | 1,571,073,035.57 | 2,048,877,844.28 | 2,093,962,255.15 | 2,586,400,343.39 |
| 非流动资产: | | | | |
| 长期股权投资 | 888,630,418.02 | 894,403,792.53 | 907,477,185.85 | 953,590,419.26 |
| 其他非流动金融资产 | 378,651,531.58 | 511,241,535.12 | 665,259,620.02 | 268,435,965.54 |
| 投资性房地产 | 11,817,815.64 | 12,044,247.39 | 12,270,679.14 | 12,497,110.89 |
| 固定资产 | 385,600,632.89 | 396,743,901.88 | 406,516,367.92 | 402,296,608.19 |
| 在建工程 | 138,948,766.86 | 136,580,677.81 | 135,018,335.85 | 130,931,342.4 |
| 无形资产 | 594,921,028.36 | 613,957,316.3 | 633,009,695.81 | 683,977,749.37 |
| 开发支出 | 513,718,922.96 | 509,972,507.42 | 502,443,595.61 | 488,269,613.29 |
| 长期待摊费用 | 1,300,290.66 | 1,439,760.74 | 1,439,760.74 | 1,579,230.82 |
| 递延所得税资产 | 50,238,891.81 | 49,688,120.47 | 53,700,447.49 | 64,077,990.71 |
| 其他非流动资产 | 739,568,479.36 | 661,828,655.94 | 660,980,622.49 | 436,631,764.47 |
| 非流动资产合计 | 3,703,396,778.14 | 3,787,900,515.6 | 3,978,116,310.92 | 3,442,287,794.94 |
| 资产总计 | 5,274,469,813.71 | 5,836,778,359.88 | 6,072,078,566.07 | 6,028,688,138.33 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 55,776,543.26 | 56,883,133.7 | 95,541,387.22 | 55,345,005.74 |
| 其中：应付票据 | 16,997,012 | 17,888,911.72 | 26,012,065.45 | 18,694,879 |
| 应付账款 | 38,779,531.26 | 38,994,221.98 | 69,529,321.77 | 36,650,126.74 |
| 预收款项 | - | 1,224,700 | 11,219.5 | 937,661.3 |
| 合同负债 | 16,843,450.06 | 385,121,067.64 | 491,956,698.99 | 74,663,207.35 |
| 应付职工薪酬 | 38,221,407.8 | 40,680,753.94 | 46,475,312.47 | 36,568,265.63 |
| 应交税费 | 4,001,446.75 | 2,555,419.87 | 2,440,499.61 | 2,067,914.68 |
| 其他应付款合计 | 85,914,391.54 | 84,446,834.33 | 50,267,221.63 | 36,689,771.53 |
| 应付股利 | 47,992.5 | - | 2,651,681.14 | - |
| 其他流动负债 | 1,155,109.09 | 34,450,817.91 | 42,894,895.96 | 2,766,829.06 |
| 流动负债合计 | 201,912,348.5 | 605,362,727.39 | 729,587,235.38 | 209,038,655.29 |
| 非流动负债: | | | | |
| 递延收益 | 73,796,803.92 | 38,796,803.92 | 41,071,202.35 | 41,166,185.23 |
| 递延所得税负债 | 65,982,655.51 | 91,301,878.95 | 112,834,888.98 | 77,751,457.74 |
| 非流动负债合计 | 139,779,459.43 | 130,098,682.87 | 153,906,091.33 | 118,917,642.97 |
| 负债合计 | 341,691,807.93 | 735,461,410.26 | 883,493,326.71 | 327,956,298.26 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,027,350,000 | 1,027,350,000 | 1,027,350,000 | 1,027,350,000 |
| 资本公积 | 61,549,655.86 | 61,549,655.86 | 61,549,655.86 | 49,615,655.87 |
| 其他综合收益 | -21,766,681.74 | -21,766,681.74 | -21,766,681.74 | 13,474,826.25 |
| 盈余公积 | 632,410,430.74 | 632,410,430.74 | 632,410,430.74 | 632,410,430.74 |
| 未分配利润 | 3,226,776,981.47 | 3,395,737,786.78 | 3,481,852,226.54 | 3,970,148,074.32 |
| 归属于母公司股东权益合计 | 4,926,320,386.33 | 5,095,281,191.64 | 5,181,395,631.4 | 5,692,998,987.18 |
| 少数股东权益 | 6,457,619.45 | 6,035,757.98 | 7,189,607.96 | 7,732,852.89 |
| 股东权益合计 | 4,932,778,005.78 | 5,101,316,949.62 | 5,188,585,239.36 | 5,700,731,840.07 |
| 负债和股东权益合计 | 5,274,469,813.71 | 5,836,778,359.88 | 6,072,078,566.07 | 6,028,688,138.33 |
| 公告日期 | 2026-08-26 | 2026-04-29 | 2026-04-29 | 2025-10-27 |
| 审计意见(境内) | | | 标准无保留意见 | |